, the most common side effects include injection site pain, fatigue, headache and muscle pain.
Novavax chief medical officer Filip Dubovsky admitted the company doesn’t yet have efficacy data against Omicron or other recent mutations, but he said their vaccine is likely to protect against the new variants as well. “It’s factual that we don’t have efficacy data against Omicron. What we do have is a technology that we think generates a broad immune response, demonstrated against a broad array of variants,” Dubovsky said.
A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. The Novavax vaccine uses an older and more conventional technology called recombinant protein, which has been used before in other vaccines targeting influenza, shingles, human papillomavirus and hepatitis B.
They did this last Thursday!